{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:17:23Z","timestamp":1792761443485,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":1160,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1093\/annonc\/mdw268","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T01:02:59Z","timestamp":1468976579000},"page":"1658-1659","source":"Crossref","is-referenced-by-count":4,"title":["PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?"],"prefix":"10.1016","volume":"27","author":[{"given":"H.","family":"Al-Ahmadie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw268_bb0010","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","article-title":"Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches","volume":"27","author":"Udager","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw268_bb0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2005.05.007","article-title":"Penile cancer","volume":"54","author":"Micali","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1093\/annonc\/mdw268_bb0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2014.10.017","article-title":"EAU guidelines on penile cancer: 2014 update","volume":"67","author":"Hakenberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1093\/annonc\/mdw268_bb0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdw268_bb0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","article-title":"Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance","volume":"74","author":"Marincola","year":"2000","journal-title":"Adv Immunol"},{"key":"10.1093\/annonc\/mdw268_bb0035","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdw268_bb0040","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw268_bb0045","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw268_bb0050","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw268_bb0055","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw268_bb0060","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw268_bb0065","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdw268_bb0070","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1093\/annonc\/mdw268_bb0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw268_bb0080","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw268_bb0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw268_bb0090","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw268_bb0095","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw268_bb0100","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw268_bb0105","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw268_bb0110","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1158\/0008-5472.CAN-15-1004","article-title":"Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy","volume":"75","author":"McDaniel","year":"2015","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw268_bb0115","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(16)00654-1","article-title":"Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma","volume":"387","author":"Netto","year":"2016","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw268_bb0120","article-title":"PDL1: the illusion of an ideal biomarker","author":"Apolo","year":"2015","journal-title":"Eur Urol Focus"},{"key":"10.1093\/annonc\/mdw268_bb0125","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw268_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/jco.2015.33.15_suppl.4501","article-title":"A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC)","volume":"33","author":"Petrylak","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419358831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419358831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/9\/1658\/6680061\/mdw268.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:01:33Z","timestamp":1624698093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419358831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0923753419358831"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw268","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}